Abstract: Phosphorus in patients with chronic renal failure metabolic disorders, elevated serum phosphate. Hyperphosphatemia can induce severe cardiovascular disease, end stage renal disease is an important factor in increased mortality. Use of phosphate binders, active vitamin D control of application of secondary hyperparathyroidism and other ways to reduce phosphorus is the key to treatment. Serious consequences due to high serum phosphorus, traditional medicines and methods of treatment there are a lot less people trying to find more effective new drugs for therapeutic purposes. This article is a new drug with the Secretary Villam hydrochloride, a non-aluminum non-calcium binders. Division Villam hydrochloride is a cationic polymer, the main components of polyacrylamide hydrochloride, combined with phosphorus. Physiological pH, the protonated-amino almost entirely through the combination of ion exchange of phosphorus in the gastrointestinal tract into a hydrated expanded several times the original volume of the gel, and not be absorbed in the intestine. Clinical trials show that the Secretary Villam hydrochloride can effectively reduce serum phosphorus levels, the effect can be comparable with the phosphate binder. Secretary Villam hydrochloride does not cause hypercalcemia, can significantly reduce the incidence of cardiovascular disease. In addition, the application of hydrochloric acid Division Villam reduce phosphorus, you can control the use of calcitriol secondary hyperparathyroidism. Currently the Division Villam hydrochloride is considered an ideal phosphate binder. But it was reported slightly lower hydrochloride Division Villam blood bicarbonate levels, reduce the fat-soluble vitamins A, D, E, K absorption and other side effects, its clinical application is limited. Long-term use hydrochloride Division Villam security is yet to be verified.
Keywords：Hyperphosphataemia; Phosphate binder; epichlorohydrin; ene hydrochloride
